Pancreatitis Trial, Recruiting NCT03334708 Sponsor: Memorial Sloan Kettering Cancer Center Condition: Pancreatitis
Back to Pancreatitis

Pancreatitis Trial, Recruiting

NCT03334708
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

This trial has several different groups (called cohorts). You may qualify for one of the following:

Group 1 – Advanced Pancreatic Cancer:

  • You have been diagnosed with locally advanced or metastatic pancreatic cancer, confirmed by imaging, tissue sample, or cell sample
  • You are planning to receive drug or other systemic treatment for your cancer
  • Your red blood cell levels (hemoglobin) are above 8 (confirm with trial site)
  • You are reasonably active and able to care for yourself (ECOG score 0–2; confirm with trial site)
  • You are at least 18 years old
  • You are willing to have a tumor biopsy performed
  • You are willing to allow previously collected tumor tissue (from past biopsies or surgery) to be used for research

Group 2 – Operable Pancreatic Cancer:

  • You have been diagnosed with pancreatic cancer, confirmed by imaging, tissue sample, or cell sample
  • You are planned to have surgery to remove the tumor as the first treatment
  • No chemotherapy or radiation is planned before your surgery
  • Your red blood cell levels (hemoglobin) are above 8 (confirm with trial site)
  • You are reasonably active and able to care for yourself (ECOG score 0–2; confirm with trial site)
  • You are at least 18 years old
  • You are willing to have a tumor biopsy performed
  • You are willing to allow previously collected tumor tissue (from past biopsies or surgery) to be used for research

Group 3 – Acute Benign Pancreatic Condition:

  • You have been diagnosed with acute pancreatitis or another sudden-onset, non-cancerous pancreatic condition
  • Your red blood cell levels (hemoglobin) are above 8 (confirm with trial site)
  • You are reasonably active and able to care for yourself (ECOG score 0–2; confirm with trial site)
  • You are at least 18 years old

Group 4 – Chronic Benign Pancreatic Condition:

  • You have been diagnosed with chronic pancreatitis or another long-term, non-cancerous, non-cyst pancreatic condition
  • Your red blood cell levels (hemoglobin) are above 8 (confirm with trial site)
  • You are reasonably active and able to care for yourself (ECOG score 0–2; confirm with trial site)
  • You are at least 18 years old

Group 5 – IPMN (a type of pancreatic cyst) Control:

  • You have been diagnosed with IPMN (a specific type of pancreatic cyst) without high-risk features, as confirmed by your doctor
  • You are at least 18 years old

Group 6 – Benign Pancreatic Cyst Control:

  • You have been diagnosed with a non-cancerous pancreatic cyst
  • You are at least 18 years old

Group 7 – Healthy Control:

  • You are at least 18 years old

Who may not be able to join:

Groups 1 & 2 – Pancreatic Cancer Groups:

  • You have received chemotherapy or radiation for pancreatic cancer in a localised setting within the past 3 months (Group 1 only)
  • Chemotherapy or radiation before surgery is planned for you (Group 2 only)
  • You currently have another active cancer, unless it is considered low-grade or low-risk (confirm with trial site)
  • You have a medical or mental health condition that could make it difficult to follow the trial's procedures

Groups 3, 4, 5, 6 & 7 – Control Groups:

  • You currently have or have previously had cancer, except for certain types of non-melanoma skin cancer
  • You have been found to carry a gene linked to higher cancer risk, or you have a strong family history suggesting a genetic tendency toward cancer
  • You have a medical or mental health condition that could make it difficult to follow the trial's procedures

Group 5 – IPMN Control only:

  • Your IPMN has high-risk features or you are already planned to have surgery to remove it

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 646-888-4188

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
30 October 2017
Est. completion
30 October 2026

Where this trial is recruiting

🇮🇱 Israel 🇺🇸 United States

Primary endpoints

Change in biomarkers to determine sensitivity and specificity of the assay to diagnose early stage pancreatic cancer

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov